Ivermectin and Fenbendazole for Cancer: Clinical Evidence Across 31 Cancer Types (2026)
Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies.
The high cost of oncology drugs-exceeding $150 billion globally in 2022-and the slow pace of new drug approvals further complicate timely patient access to effective therapies. In this context, drug repurposing-the strategy of identifying new therapeutic uses for existing drugs-has emerged as a promising approach to accelerate cancer treatment development while reducing costs and safety risks.
Among repurposed candidates, antiparasitic drugs such as fenbendazole, mebendazole, and ivermectin have attracted considerable attention due to their demonstrated anticancer activities across multiple preclinical models and emerging clinical case reports. These agents, originally developed to treat parasitic infections, exert multiple mechanisms of actions on cancer cells, including disruption of microtubule dynamics, interference with metabolic pathways, and modulation of oncogenic signaling.
Fenbendazole, a benzimidazole derivative widely used in veterinary medicine, has shown potent anticancer effects by destabilizing microtubules, inducing G2/M cell cycle arrest, and impairing glucose metabolism through inhibition of glucose transporters (GLUT1/4) and hexokinase activity. These actions lead to reduced glycolysis and lactate production, effectively starving cancer cells and overcoming drug resistance, particularly in 5-fluorouracil-resistant colorectal cancer models (Bai et al., 2009; Oral Fenbendazole for Cancer Therapy, 2024; Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant cells, 2022). However, fenbendazole’s poor water solubility and limited oral bioavailability present challenges for achieving therapeutic systemic levels, necessitating formulation improvements and pharmacokinetic optimization.
Mebendazole, a structurally related benzimidazole with better bioavailability and a longer history of human use, similarly disrupts microtubule polymerization and induces apoptosis. It has demonstrated anticancer activity in diverse malignancies, including ovarian cancer, chronic myeloid leukemia, and glioblastoma, with evidence of synergistic effects when combined with tyrosine kinase inhibitors and other chemotherapeutics (Potential and mechanism of mebendazole, 2020; Anticancer potential of mebendazole against chronic myeloid leukemia, 2022; Repurposing Drugs in Oncology, 2014). Mebendazole’s ability to cross the blood-brain barrier further supports its investigation in brain tumors.
Ivermectin, a macrocyclic lactone antiparasitic, exhibits broad-spectrum anticancer effects through mechanisms distinct from benzimidazoles. It inhibits key oncogenic pathways such as STAT3, Wnt/β-catenin, and AKT/mTOR, induces oxidative stress, promotes apoptosis and autophagy, and targets cancer stem cells. Preclinical studies have demonstrated its efficacy across more than 20 cancer types, including breast, colon, lung, and hematologic malignancies, with promising activity against drug-resistant and metastatic tumors. Its favorable safety profile at standard doses supports combination regimens with fenbendazole and mebendazole, which may enhance therapeutic outcomes through complementary mechanisms.
Despite encouraging preclinical and anecdotal clinical evidence, these antiparasitic agents remain largely experimental in oncology, with limited randomized controlled trials and regulatory approval for cancer indications. Variability in dosing protocols, access issues, and concerns about off-label use underscore the need for rigorous clinical evaluation. Nonetheless, their low cost, oral administration, and multi-targeted anticancer properties position fenbendazole, mebendazole, and ivermectin as attractive candidates for adjunctive cancer therapy, especially in resource-limited settings.
References:
The high cost of oncology drugs-exceeding $150 billion globally in 2022-and the slow pace of new drug approvals further complicate timely patient access to effective therapies. In this context, drug repurposing-the strategy of identifying new therapeutic uses for existing drugs-has emerged as a promising approach to accelerate cancer treatment development while reducing costs and safety risks.
Among repurposed candidates, antiparasitic drugs such as fenbendazole, mebendazole, and ivermectin have attracted considerable attention due to their demonstrated anticancer activities across multiple preclinical models and emerging clinical case reports. These agents, originally developed to treat parasitic infections, exert multiple mechanisms of actions on cancer cells, including disruption of microtubule dynamics, interference with metabolic pathways, and modulation of oncogenic signaling.
Fenbendazole, a benzimidazole derivative widely used in veterinary medicine, has shown potent anticancer effects by destabilizing microtubules, inducing G2/M cell cycle arrest, and impairing glucose metabolism through inhibition of glucose transporters (GLUT1/4) and hexokinase activity. These actions lead to reduced glycolysis and lactate production, effectively starving cancer cells and overcoming drug resistance, particularly in 5-fluorouracil-resistant colorectal cancer models (Bai et al., 2009; Oral Fenbendazole for Cancer Therapy, 2024; Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant cells, 2022). However, fenbendazole’s poor water solubility and limited oral bioavailability present challenges for achieving therapeutic systemic levels, necessitating formulation improvements and pharmacokinetic optimization.
Mebendazole, a structurally related benzimidazole with better bioavailability and a longer history of human use, similarly disrupts microtubule polymerization and induces apoptosis. It has demonstrated anticancer activity in diverse malignancies, including ovarian cancer, chronic myeloid leukemia, and glioblastoma, with evidence of synergistic effects when combined with tyrosine kinase inhibitors and other chemotherapeutics (Potential and mechanism of mebendazole, 2020; Anticancer potential of mebendazole against chronic myeloid leukemia, 2022; Repurposing Drugs in Oncology, 2014). Mebendazole’s ability to cross the blood-brain barrier further supports its investigation in brain tumors.
Ivermectin, a macrocyclic lactone antiparasitic, exhibits broad-spectrum anticancer effects through mechanisms distinct from benzimidazoles. It inhibits key oncogenic pathways such as STAT3, Wnt/β-catenin, and AKT/mTOR, induces oxidative stress, promotes apoptosis and autophagy, and targets cancer stem cells. Preclinical studies have demonstrated its efficacy across more than 20 cancer types, including breast, colon, lung, and hematologic malignancies, with promising activity against drug-resistant and metastatic tumors. Its favorable safety profile at standard doses supports combination regimens with fenbendazole and mebendazole, which may enhance therapeutic outcomes through complementary mechanisms.
Despite encouraging preclinical and anecdotal clinical evidence, these antiparasitic agents remain largely experimental in oncology, with limited randomized controlled trials and regulatory approval for cancer indications. Variability in dosing protocols, access issues, and concerns about off-label use underscore the need for rigorous clinical evaluation. Nonetheless, their low cost, oral administration, and multi-targeted anticancer properties position fenbendazole, mebendazole, and ivermectin as attractive candidates for adjunctive cancer therapy, especially in resource-limited settings.
A publicly accessible compilation hosted by OneDayMD documents more than 550 anecdotal cancer cases, categorized across 31 different cancer types, reporting tumor regression, stabilization, or remission while using these agents. In many of these reports, the drugs were used alongside conventional cancer therapies or in combination with various adjunctive supplements.
The list of fenbendazole and ivermectin related cancer case reports below is organised alphabetically by cancer type.
Despite numerous anecdotal reports and media coverage suggesting that fenbendazole, mebendazole and ivermectin may be effective in treating metastatic cancer, there is currently not enough clinical literature supporting its use as an anti-cancer agent.
This work-in-progress guide aims to compile anecdotal success stories and case reports to help establish a stronger scientific foundation for further investigation of fenbendazole (FBZ), ivermectin and mebendazole as part of a potential combination or adjunctive therapy for cancer.
The following success stories were gathered from various web and social media sources, providing anecdotal, crowd-sourced information.
This work-in-progress guide aims to compile anecdotal success stories and case reports to help establish a stronger scientific foundation for further investigation of fenbendazole (FBZ), ivermectin and mebendazole as part of a potential combination or adjunctive therapy for cancer.
The following success stories were gathered from various web and social media sources, providing anecdotal, crowd-sourced information.
The list of fenbendazole and ivermectin related cancer case reports below is organised alphabetically by cancer type.
Notes:
- Some cancer types have more than 10 case reports, so we’ve created dedicated articles for each to make updates and management easier. To view the complete set of case reports, click “Read More” under the relevant cancer type.
- Breast Cancer Success Stories (77 cases)
- Brain Cancer (including Glioblastoma) (119 cases)
- Bile Duct Cancer (Cholangiocarcinoma) (4 cases)
- Bladder Cancer Success Stories (including kidney cancer) (29 cases)
- Cervical Cancer (6 cases)
- Colorectal Cancer (including Appendix cancer) (51 cases)
- Esophageal and Stomach cancer (21 cases)
- Endometrial Cancer (9 cases)
- Gastric (Stomach) cancer (see Esophageal and Stomach Cancer) (21 cases)
- Head and Neck Cancer (15 cases)
- Kidney Cancer Case Series (including urinary (urothelial) bladder cancer) (27 cases)
- Liver Cancer (HepatoCellular Cancer) (3 cases)
- Lung Cancer (40 cases)
- Leukemia (9 cases)
- Lymphoma (23 cases)
- Melanoma (refer to Skin Cancer)
- Multiple Myeloma (5 cases)
- Myelodysplastic Syndrome
- Oral Cancer (refer to Head and Neck)
- Ovarian Cancer (13 cases)
- Pancreatic Cancer (37 cases)
- Prostate Cancer (65 cases)
- PEComa (1 case)
- Sarcoma (4 cases)
- Skin Cancer (12 cases)
- Throat Cancer (refer to 'Head and Neck')
- Thymus cancer
- Thyroid Cancer (4 cases)
- Turbo Cancer (Aggressive Cancer)
- Testicular Cancer
- Uterine cancer (refer to Endometrial Cancer above) (7 cases)
- Others
Disclaimers:
- This article is for educational purposes only and does not constitute medical advice. Ivermectin is not approved by the FDA for cancer treatment, and its use in this context is experimental. Always consult a qualified healthcare professional before starting any new treatment, especially if undergoing conventional cancer therapies.
- Our aim here isn't to replace your doctors' advice. It is intended as a sharing of knowledge and information. Do take note that cancer is a continuous struggle between the immune system and the cancer cells. Cancer treatments are meant to assist the immune system in this battle.
- Cancer treatment should be part of a multi-modal approach in order to provide the best possible outcome. Diet and lifestyle changes are meant to run alongside conventional treatment. They are complementary, not alternative.
- Cancer care is a team effort with the patient at the centre. Care should be supervised and coordinated by a primary healthcare provider. Patients with cancer should consult with their regular oncologist as well as an integrative provider/oncologist, in addition to their primary care provider and the supporting nurses, dieticians and other allied healthcare professionals.
- While the term 'alternative' might imply opposition to conventional oncology, we prefer 'complementary,' 'integrated,' or 'holistic.' These terms better reflect the role of these strategies as part of a personalized value-added menu of strategies, ensuring the most effective and safe solutions for patients.
- Integrating a repurposed drug doesn't mean rejecting modern medicine — It enhances it and offers a more comprehensive approach to wellness and healing. By combining conventional cancer management with root-cause resolution, this model creates a path to sustained recovery and resilience.
- Fenbendazole vs Ivermectin for cancer
- Top 10 cancer fighting supplements
- Joe Tippens Protocol Fenbendazole
- Best Ivermectin Dosage for Humans with Cancer or Different Cancer Types
- Cancer as a Metabolic & Immune Disease: Diet, Drugs, and Science Explained (2026 Public Guide)
Like and Follow us for more updates on X/Twitter: One Day MD on X.com.
Ivermectin and mebendazole, both approved for human use, are now available in the U.S.
Researched and approved by Dr. Peter McCullough.
Researched and approved by Dr. Peter McCullough.
- Prescribed by licensed medical professionals
- Compounded and dispensed by a licensed US-based pharmacy
- Approved for human use
Where to buy Ivermectin and Mebendazole Formula: Available on The Wellness Company's website. Here is the link: Ivermectin and Mebendazole.
.png)
Comments
Post a Comment